Review: Papanicolaou and wet-mount smears have low sensitivity but high specificity for detecting vaginal trichomoniasis


Question
In women, what are the sensitivity and specificity of the Papanicolaou (Pap) and wet-mount smears for detecting vaginal trichomoniasis?

Data sources
Studies were identified by searching MEDLINE (1976 to February 1998) and reference lists of relevant articles.

Study selection
2 reviewers independently selected studies that described diagnostic tests for vaginal trichomoniasis, used trichomonas culture as the diagnostic standard, and were published in any language.

Data extraction
2 reviewers independently extracted data on study setting and validity of study design and for 2 × 2 contingency tables. The quality of study methods was classified as level I (2 criteria fulfilled), level II (1 criterion fulfilled), or level III (no criteria fulfilled). The following criteria were used: Consecutive patients were evaluated prospectively, the test result did not influence the decision to apply the diagnostic test, and the test of interest and the diagnostic standard were blinded and independently examined. Disagreement was resolved by discussion.

Main results
30 studies (31 comparisons, 9501 women) met the selection criteria (level I, 12 studies; level II, 15 studies; and level III, 4 studies). 7 studies (2958 women) examined the test characteristics of the Pap smear. The pooled total prevalence was 18% (range 6% to 73%); the weighted mean sensitivity and specificity and the likelihood ratios are shown in the Table. All 30 studies examined the test characteristics of the wet-mount smear. The pooled total prevalence was 19% (range 6% to 73%); the weighted mean sensitivity and specificity and the likelihood ratios are shown in the Table.

Test characteristics of the Papanicolaou (Pap) and wet-mount smears for detecting vaginal trichomoniasis*

<table>
<thead>
<tr>
<th>Type of smear</th>
<th>Number of comparisons</th>
<th>Study quality†</th>
<th>Weighted mean sensitivity (95% CI)</th>
<th>Weighted mean specificity (CI)</th>
<th>+LR</th>
<th>−LR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pap</td>
<td>7</td>
<td>All studies</td>
<td>58% (43 to 73)</td>
<td>97% (95 to 100)</td>
<td>19.3</td>
<td>0.4</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>Level I</td>
<td>57% (51 to 63)</td>
<td>97% (93 to 100)†</td>
<td>19.0</td>
<td>0.4</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>Level II</td>
<td>49% (18 to 80)</td>
<td>99% (97 to 100)†</td>
<td>49.0</td>
<td>0.5</td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>Level III</td>
<td>89% (79 to 98)</td>
<td>88% (71 to 100)</td>
<td>7.4</td>
<td>0.1</td>
</tr>
<tr>
<td>Wet mount</td>
<td>31</td>
<td>All studies</td>
<td>68% (62 to 74)</td>
<td>99.9% (99.8 to 100)</td>
<td>680</td>
<td>0.3</td>
</tr>
<tr>
<td></td>
<td>12</td>
<td>Level I</td>
<td>58% (51 to 66)†</td>
<td>99.8% (99.5 to 100)</td>
<td>290</td>
<td>0.4</td>
</tr>
<tr>
<td></td>
<td>15</td>
<td>Level II</td>
<td>72% (62 to 81)†</td>
<td>100% (100)</td>
<td>∞</td>
<td>0.3</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>Level III</td>
<td>82% (67 to 97)†</td>
<td>100% (100)</td>
<td>∞</td>
<td>0.2</td>
</tr>
</tbody>
</table>

*Abbreviations defined in Glossary. LRs calculated from data in article.
†Level I = high quality; level III = low quality.
‡Statistically significant heterogeneity is present.

Commentary
Trichomoniasis is the second most common sexually transmitted disease in the United States after human papillomavirus (HPV) (1). Trichomomas infections and bacterial vaginosis have been associated with premature rupture of membranes, pelvic infections after surgery, and potential infertility, which makes treatment of these infections an appropriate public health goal (2).

Wiese and colleagues have accurately calculated the characteristics of a Pap test for trichomonads and of a wet mount to diagnose trichomoniasis from a group of studies meeting stringent criteria. The weighted averages of sensitivity and specificity are easily used in Bayes’ theorem to help clinicians decide when to test and when to treat a woman for trichomoniasis.

Clinically, the treatment-threshold probability is determined by the ratio of the cost of treatment to the benefit of treatment. When the cost of trichomomas treatment (including adverse events and antimicrobial resistance) is low and the benefit is high, the treatment-threshold probability is low (between 10% and 20%).

If the prevalence (or pretest probability) of trichomoniasis in the community is greater than the treatment-threshold probability, then empirical treatment of all women with trichomonads on their Pap smear is appropriate. No further testing is indicated because a negative wet-mount test result is not sufficiently powerful to pull the post-test probability below the treatment-threshold probability.

Diane Harper, MD, MSc, MPH
Dartmouth Medical School
Lebanon, New Hampshire, USA

References

ACP Journal Club November/December 2000 ©ACP-ASIM; BMJ 113